Synlogic (SYBX) Stock Price, News & Analysis

Company Overview

Synlogic, Inc. is a biotechnology company focused on developing medicines based on synthetic biology. Its platform engineers probiotic bacteria, primarily strains of Escherichia coli, to perform specific therapeutic functions inside the gastrointestinal tract, such as consuming disease-associated metabolites or producing beneficial compounds.

The company’s development programs have targeted rare metabolic disorders. Notable candidates have included SYNB1618 and SYNB1934 for phenylketonuria, a condition involving impaired processing of phenylalanine, and SYNB8802 for hyperoxaluria, a disorder characterized by excessive oxalate production. Synlogic has also investigated its technology in other metabolic diseases and therapeutic areas.

Founded in 2013 and headquartered in Cambridge, Massachusetts, Synlogic advanced its programs through clinical development with an initial focus on the United States and potential applications in international markets. The company’s research has centered on using engineered living medicines to address conditions that may be difficult to treat with conventional pharmaceutical approaches.

Key Stats

• Today's Range: $1.11 to $1.16
• 50-Day Range: $0.67 to $1.23
• 52-Week Range: $0.54 to $1.87
• Volume: 4,292 shs
• Average Volume: 66,816 shs
• Market Capitalization: $13.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Synlogic Stock Analysis - MarketRank™

Synlogic scored higher than 6% of companies evaluated by MarketBeat, and ranked 865th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Synlogic has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Synlogic has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Synlogic are expected to grow in the coming year, from ($2.71) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Synlogic is -4.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synlogic is -4.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synlogic has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SYBX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synlogic does not currently pay a dividend.

Dividend Growth

Synlogic does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Synlogic has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Synlogic this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synlogic insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.62% of the stock of Synlogic is held by insiders.

Percentage Held by Institutions

63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/13/2025
• Today: 10/03/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SYBX
• CIK: 1527599
• Web: www.synlogictx.com
• Phone: (617) 401-9975
• Fax: 512-681-5201
• Employees: 80
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.47%
• Return on Assets: -18.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.65
• Quick Ratio: 2.65

Sales & Book Value

• Annual Sales: $8 thousand
• Price / Sales: 1,699.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 1.02

Miscellaneous

• Outstanding Shares: 12,249,000
• Free Float: 11,392,000
• Market Cap: $13.60 million
• Optionable: No Data
• Beta: 0.50